Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT/CT

Radiat Oncol. 2014 Nov 26:9:253. doi: 10.1186/s13014-014-0253-z.

Abstract

Background: Stereotactic ablative body radiotherapy (SABR) has been proposed as a definitive treatment for patients with inoperable primary renal cell carcinoma. However, there is little documentation detailing the radiobiological effects of hypofractionated radiation on healthy renal tissue.

Findings: In this study we describe a methodology for assessment of regional change in renal function in response to single fraction SABR of 26 Gy. In a patient with a solitary kidney, detailed follow-up of kidney function post-treatment was determined through 3-dimensional SPECT/CT imaging and (51)Cr-EDTA measurements. Based on measurements of glomerular filtration rate, renal function declined rapidly by 34% at 3 months, plateaued at 43% loss at 12 months, with minimal further decrease to 49% of baseline by 18 months.

Conclusions: The pattern of renal functional change in (99m)Tc-DMSA uptake on SPECT/CT imaging correlates with dose delivered. This study demonstrates a dose effect relationship of SABR with loss of kidney function.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Renal Cell / surgery*
  • Humans
  • Kidney / diagnostic imaging*
  • Kidney / radiation effects*
  • Kidney Neoplasms / surgery*
  • Multimodal Imaging
  • Radiation Injuries / diagnostic imaging*
  • Radiopharmaceuticals
  • Radiosurgery / adverse effects*
  • Technetium Tc 99m Dimercaptosuccinic Acid
  • Tomography, Emission-Computed, Single-Photon
  • Tomography, X-Ray Computed

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Dimercaptosuccinic Acid